by Dennis Crouch
On July 14, 2026, the full Senate Judiciary Committee held its hearing "From Genes to Machines: The Patent Eligibility Debate," which Chairman Chuck Grassley described as the first time the whole committee, rather than Senator Thom Tillis's Intellectual Property Subcommittee, has taken up the Patent Eligibility Restoration Act of 2025, S. 1546, 119th Cong. (2025) (companion H.R. 3152). PERA would erase the judicial exceptions to Section 101 that the Supreme Court expanded in Alice and Mayo, and replace them with a narrow statutory list of things that cannot be patented. No vote or markup was scheduled, and Grassley was candid that many members are still studying the bill (i.e., do not yet support the legislation).
Tillis, who is retiring at the end of this Congress, said he is willing to change PERA's human-gene language, and he asked Debra Leonard, the witness most opposed to aspects of the bill to send him wording that would, in her view, preserve Myriad.
Four witnesses testified, split evenly. Andrei Iancu (former USPTO Director) and Sue Peschin (Alliance for Aging Research) urged passage. J. John Lee (Computer and Communications Industry Association) and Dr. Leonard (Professor Emerita of Pathology at the University of Vermont and a past president of the Association for Molecular Pathology, the named plaintiff in Myriad) asked the committee to leave current law alone. I found Dr. Leonard's discussion of gene patenting outdated at this point - that gold rush is over. The isolated natural sequences behind her 1990s licensing letters have long since been sequenced and published, and those patents are expired, so a fresh claim to one would fail for want of novelty or nonobviousness, whatever Myriad says at the eligibility threshold. What is worth claiming today runs the other way, toward the engineered constructs she herself credited, CRISPR edits and gene therapies, and the cDNA that Myriad already treats as eligible. But, she also mentioned basic correlations associated with human health - the diagnostic discoveries that continue to be ripe areas for research and that are largely blocked by Mayo.
To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.


